that’s a title Ramanan Laxminarayan Editorial published in Lancet this week.Part of the rationale for this review is a new study published this week Antimicrobial Resistance Collaborator (2022). In a systematic review of the impact of antimicrobial resistance (AMR) on mortality, the authors found:

…an estimated 495 million (3 62–6 57) deaths related to bacterial AMR in 2019, of which 1 27 million (95% UI 0 911–1 71) were due to bacterial AMR. At the regional level, we estimate the highest all-age mortality rate attributable to resistance in sub-Saharan Africa, at 27·3 deaths per 100,000 people (20·9-35·3), while in UM Lassia had the lowest rate of 6.5 deaths per 100,000 population (4.3–9.4). In 2019, lower respiratory tract infections caused more than 1.5 million drug resistance-related deaths, making it the most burdensome infectious disease syndrome. Six leading pathogens of death associated with drug resistance (Escherichia coliFollowed by Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumanniiand Pseudomonas aeruginosa) contributed to 929 000 (660 000–1 270 000) deaths due to AMR and 357 million (2 62–4 78) AMR-related deaths in 2019.

The following are the diseases with the highest mortality burden due to AMR.